Department of Neurosurgery, Geisinger Neuroscience Institute, 100 N Academy Ave, 17822, Geisinger, Danville, PA, USA.
Department of Neurosurgery, Saarland University Medical Center, Homburg, Germany.
Clin Neuroradiol. 2022 Jun;32(2):369-374. doi: 10.1007/s00062-021-01063-9. Epub 2021 Jul 27.
Pooled data of randomized controlled trials investigating mechanical thrombectomy (MT) to treat anterior circulation large vessel occlusion have demonstrated safety and effectiveness across all age groups, including ≥ 80 years of age; however, only a few nonagenarians were in the ≥ 80 years subgroup. Therefore, the benefit of MT in nonagenarians is mostly unknown.
Two comprehensive stroke centers retrospectively reviewed all acute ischemic stroke patients who underwent MT for anterior circulation large vessel occlusion (LVO) stroke between February 2016 and August 2020. Revascularization TICI2b/3, symptomatic intracranial hemorrhage (ICH), and functional outcome using modified Rankin scale (mRS) were assessed for cases aged < 80 years, 80-89 years, and 90-99 years. Favorable functional outcome was defined as mRS 0-2 or reaching the prestroke mRS and moderate as mRS 0-3.
The final data set comprised a total of 736 cases. Of these, 466 aged < 80 years, 219 aged 80-89 years, and 51 aged 90-99 years. In nonagenarians, TICI 2b/3 revascularization was observed in 84.3% while symptomatic ICH was observed in 4%. These rates were similar to 80-89 years and < 80 years age groups. Favorable and moderate functional outcome as well as death rates differed significantly between nonagenarians and < 80 years (19.6%, 29.4%, 51.0% vs 47.9%, 60.7%, 18.7%, respectively, p < 0.001), but were similar between nonagenarians and octogenarians (29.7%, 38.8%, 38.8%, p = 0.112-0.211).
A moderate outcome among nonagenarians was observed in about 30%, while mortality rates were about 50%. Withholding mechanical thrombectomy does not appear justifiable, although the absolute treatment effect among nonagenarians remains unknown.
对机械取栓术(MT)治疗前循环大血管闭塞的随机对照试验进行的汇总数据分析表明,该治疗方法在所有年龄段均安全有效,包括年龄≥80 岁的患者;然而,≥80 岁年龄组中仅有少数 90 岁以上的患者。因此,机械取栓术对 90 岁以上患者的疗效知之甚少。
两家综合卒中中心回顾性分析了 2016 年 2 月至 2020 年 8 月期间接受 MT 治疗的前循环大血管闭塞性卒中的所有急性缺血性卒中患者。评估了年龄<80 岁、80-89 岁和 90-99 岁的患者的血管再通程度(TICI2b/3)、症状性颅内出血(ICH)和改良 Rankin 量表(mRS)评分的功能预后。良好的功能预后定义为 mRS 0-2 分或达到治疗前的 mRS 评分,而中度改善定义为 mRS 0-3 分。
最终数据集共包括 736 例患者。其中 466 例年龄<80 岁,219 例年龄 80-89 岁,51 例年龄 90-99 岁。90 岁以上患者的 TICI2b/3 再通率为 84.3%,症状性 ICH 发生率为 4%。这些比例与 80-89 岁和<80 岁年龄组相似。90 岁以上患者的良好和中度功能预后以及死亡率与<80 岁患者相比差异有统计学意义(19.6%、29.4%、51.0%与 47.9%、60.7%、18.7%,p<0.001),但与 80 岁以上患者相比差异无统计学意义(29.7%、38.8%、38.8%,p=0.112-0.211)。
90 岁以上患者的预后较好比例约为 30%,死亡率约为 50%。机械取栓术并非完全禁忌,但 90 岁以上患者的绝对治疗效果尚不清楚。